Inhibition of platelet activation by clopidogrel in type II diabetes mellitus patients
Phase 4
Completed
- Conditions
- diabetes mellitus / diabetes1003553410012653
- Registration Number
- NL-OMON32343
- Lead Sponsor
- niversitair Medisch Centrum Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 24
Inclusion Criteria
1. healthy controls (matched by age and gender)
2. type II DM patients, treated with oral bloodglucose lowering agents (biguanides or sulfonylurea derivates)
Exclusion Criteria
pregnancy; use of anti-epileptic drugs; use of acetylsalicylacid, NSAID, GPIIb-IIa antagonists, heparin or thrombolytica; known diabetic retinopathy; smoking; hypersensitivity to the drug substance or any component of the product; severe liverfunctiondisorder; active pathological bleeding such as peptic ulcer or intracranial hemorrhage; breastfeeding; surgery or dental operation 7 days prior or 7 days after the start of clopidogrel intake; galactose intolerance, lapp lactase deficiency or glucose galactose malabsorbtion
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method